Showing 8031-8040 of 8349 results for "".
- Syneron Kicks Off New Campaignhttps://practicaldermatology.com/news/20121002-syneron_kicks_off_new_campaign/2459721/Syneron Medical Ltd. launched a new Break Up. Get Even! campaign for its elure product line. As part of the campaign, five winners will receive a complete elure range of products ($335 value) to “break up” stubborn discoloration and “get even” skin tone. The campaign is run through the company's
- Bovie Medical Promotes Double Warranty, Free Goodshttps://practicaldermatology.com/news/20121002-bovie_medical_promotes_double_warranty_free_goods/2459723/Bovie Medical Corporation started its Fall Festival of Fun promotion now through December 31, 2012. During the promotion, customers receive an increased value of a double warranty and free goods when purchasing the Aaron® 1250, Aaron® 2250, or Aaron® 3250. To find out more information contact a loca
- Janssen Launches Online Resource for Healthcare Professionalshttps://practicaldermatology.com/news/20121002-janssen_launches_online_resource_for_healthcare_professionals/2459725/Janssen Scientific Affairs recently launched a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. JanssenMD (www.janssenmd.com) is a web-based application is designed for use on desktops, tablets,
- Physician Pessimism, Dissatisfaction Highhttps://practicaldermatology.com/news/20120928-physician_pessimism_dissatisfaction_high/2459726/More than half of American physicians participating in a recent survey say they plan to significantly modify their practice patterns over the next one to three years, new research suggests. They report plans to cut back on patients seen, work part-time, switch to concierge medicine, retire, or take
- Star Scientific's Rock Creek Pharmaceuticals, Inc. Launches New Producthttps://practicaldermatology.com/news/20120926-star_scientifics_rock_creek_pharmaceuticals_inc_launches_new_product/2459728/Star Scientific, Inc., through its wholly owned subsidiary Rock Creek Pharmaceuticals, Inc., announced the new Anatabloc face cream, which is available on the cosmetic portion of the Anatabloc website and in select dermatology practices. The pro
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree
- Suneva Medical Launches ReGenica Skincarehttps://practicaldermatology.com/news/20120809-suneva_medical_launches_regenica_skincare/2459753/Suneva Medical launched ReGenica Skincare, a three-product rejuvenation system, that contains a variety of proteins and growth factors in a serum-free solution known as Multipotent CCM Complex, says the company. In one study, ReGenica Advanced Re
- Cone Health Pioneers Use of Fabric That Healshttps://practicaldermatology.com/news/20120726-cone_health_pioneers_use_of_fabric_that_heals/2459762/Studies find that hospital linens and gowns can be transformed into therapeutic tools when made with a smooth, antimicrobial fabric called DermaTherapy. Researchers found that patients using DermaTherapy developed 81.5 percent fewer be
- Makucell Unveils Renewnthttps://practicaldermatology.com/news/20120627-makucell_unveils_renewnt/2459779/Makucell, Inc., a pioneering regenerative biotechnology company, recently released the Renewnt (pronounced “Re-new-int”) brand. Renewnt's proprietary ingredient, Asymmtate, is a new approach to cellular aging, optimizing signals in the Wnt (pronounced “
- GlaxoSmithKline Launches Combination Trials for Metastatic Melanomahttps://practicaldermatology.com/news/20120604-glaxosmithkline_launches_combinations_trial_for_metastatic_melanoma/2459792/GlaxoSmithKline has begun a Phase III program evaluating the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with BRAF mutation-positive metastatic cutaneous melanoma. The COMBI-d (Combination of MEK and B